Acumen Pharmaceuticals, Inc. (ABOS) News
Filter ABOS News Items
ABOS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ABOS News From Around the Web
Below are the latest news stories about ACUMEN PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ABOS as an investment opportunity.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call TranscriptAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Call Transcript November 13, 2023 Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.24, expectations were $-0.31. Presentation: Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharma Third Quarter 2023 Conference Call and Webcast. At this time, all participants are in […] |
Q3 2023 Acumen Pharmaceuticals Inc Earnings CallQ3 2023 Acumen Pharmaceuticals Inc Earnings Call |
Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business UpdateKey Developments Include Progress on Alzheimer's Treatment and New Funding Agreements |
Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?InvestorsObserver issues critical PriceWatch Alerts for TIVC, TYGO, TATT, PSTV, and ABOS. |
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVenturesProvides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), today announced that it has e |
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business HighlightsInitiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023 Announced global collaboration and license agreement with Halozyme for development of a subcutaneous formulation of ACU193 Initiation of a Phase 1 study to support a subcutaneous dosing option of ACU193 expected in mid-2024 Announced a credit facility of up to $50 million from K2 HealthVentures, to |
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s CuresUnveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. |
3 Promising Biotech Stocks Flying Under the RadarBreakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. |
Acumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceCHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 14, 2023 at 2:25 p.m. ET. The live webcast may be accessed under the Investors tab on www. |
Q3 2023 Halozyme Therapeutics Inc Earnings CallQ3 2023 Halozyme Therapeutics Inc Earnings Call |